US 20170042791A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0042791 A1 Ghalili et al. (43) Pub. Date: Feb. 16, 2017 (54) TOPICAL COMPOSITIONS COMPRISING A6IR 8/73 (2006.01) HYDROXY ACIDS AND CANNABINOIDS A6IR 8/92 (2006.01) FOR SKIN CARE A6IR 9/00 (2006.01) A6II 45/06 (2006.01) (71) Applicant: Kannannovations LLC, New York, A636/85 (2006.01) NY (US) A6II 3/19 (2006.01) A6II 3/94 (2006.01) (72) Inventors: Babek Ghalili, New York, NY (US); A63L/92 (2006.01) Kevin McGovern, Palm Beach, FL A63L/366 (2006.01) (US) A61O 19/00 (2006.01) (52) U.S. Cl. (73) Assignee: Kannannovations LLC, New York, CPC ................. A61K 8/97 (2013.01); A61O 19/00 NY (US) (2013.01); A61O 19/08 (2013.01); A61K 8/365 (2013.01); A61K 8/498 (2013.01); A61K 8/345 (21) Appl. No.: 15/233,251 (2013.01); A61K 8/731 (2013.01); A61K 8/922 (22) Filed: Aug. 10, 2016 (2013.01); A61K 9/0014 (2013.01); A61 K 45/06 (2013.01); A61K 36/185 (2013.01); Related U.S. Application Data A61K 31/19 (2013.01); A61K 31/194 (2013.01); A61K 31/192 (2013.01); A61 K (60) Provisional application No. 62/203,698, filed on Aug. 3 1/366 (2013.01) 11, 2015. Publication Classification (57) ABSTRACT (51) Int. Cl. The present invention relates to compositions and methods A 6LX 8/97 (2006.01) for the prevention and treatment of skin disorders and for the A61O 19/08 (2006.01) rejuvenation of the skin. In particular, the application A6 IK 8/365 (2006.01) describes topical compositions and methods of treatments A6I SA9 (2006.01) comprising the combined use of one or more cannabinoids A6 IK 8/34 (2006.01) and one or more hydroxy acids in a suitable carrier. Patent Application Publication Feb. 16, 2017. Sheet 1 of 5 US 2017/0042791 A1 FIGURE 1 Tetrahydrocannabinol (THC) Tetrahydrocannabinol Carboxylic Acid (THCA) Cannabidiol (CBD) Cannabidiol Carboxylic Acid (CBDA) Patent Application Publication Feb. 16, 2017. Sheet 2 of 5 US 2017/0042791 A1 FIGURE 1 (continued) Cannabigerol (CBG) HO Cannabichromene (CBC) Cannabinol (CBN) Tetrahydrocannabivarin (THCV) Patent Application Publication Feb. 16, 2017 Sheet 3 of 5 US 2017/0042791 A1 FIGURE 2 Baseline Day 28 Patent Application Publication Feb. 16, 2017. Sheet 4 of 5 US 2017/0042791 A1 FIGURE 3 Patent Application Publication Feb. 16, 2017 Sheet 5 of 5 US 2017/0042791 A1 FIGURE 4 Baseline Day 28 US 2017/0042791 A1 Feb. 16, 2017 TOPCAL COMPOSITIONS COMPRISING 0006. Accordingly, there is a need in the art for improved HYDROXY ACDS AND CANNABINOIDS treatment options for improving skin condition, delaying FOR SKN CARE and reducing the effects of skin aging and treating or preventing skin disorders. CROSS-REFERENCE TO RELATED APPLICATIONS SUMMARY OF THE INVENTION 0007. It is, therefore, an object of the invention to provide 0001. This application claims the benefit of priority from Solutions to the aforementioned problems, among other U.S. Provisional Application No. 62/203,698, filed Aug. 11, objects. 2015, the content of which is incorporated by reference in its 0008. One embodiment of the invention is a topical entirety. composition for treating skin that comprises a therapeuti cally effective amount of at least one cannabinoid and a FIELD OF THE INVENTION therapeutically effective amount of a hydroxy acid in a topically acceptable carrier. The at least one cannabinoid and 0002 The present invention relates to the use of hydroxy at least one hydroxy acid may optionally be the only active acids and cannabinoids for skin care. ingredients of the composition. In one aspect of the inven tion, the cannabinoids are present in the topical composition BACKGROUND OF THE INVENTION in a concentration between 0.1 and 30% by weight of the composition. Preferably, the cannabinoids are one or more 0003. The skin is the largest organ of the body, with a of a natural phytocannabinoid, an organic cannabinoid, an Surface area of 18 Square feet. In the epidermis, the kera endocannabinoid, a cannabinoid analog, a cannabinoid tinocytes produce keratin, a protein that gives skin its derivative, a synthetic cannabinoid and a cannabinoid recep strength and flexibility and waterproofs the skin surface. tor agonist. The hydroxy acid is an alpha hydroxy acid, a Collagen and elastic fibers in the dermis give strength to the beta hydroxy acid or a combination thereof. In one aspect of skin. The skin is continuously exposed to changes in the the invention, the hydroxy acid is an alpha hydroxy acid, and external environment, including oxidative insults, heat, cold, the alpha hydroxy acid is lactic acid, citric acid, glycolic UV radiation, injury, and mechanical stresses. The stratum acid, mandelic acid, benzylic acid, malic acid, tartaric acid, corneum, composed of terminally differentiated keratino gluconolactone, galactonolactone, glucuronolactone, galac cytes, constitutes the natural barrier that prevents loss of turonolactone, gulonolactone, ribonolactone, Saccharic acid water and penetration of infectious agents, such as bacteria lactone, pantoylactone, glucoheptonolactone, mannonolac and viruses, and foreign particles. Keratin intermediate tone, or galactoheptonolactone. In a different aspect of the filaments provide the cells with mechanical resilience and invention, the hydroxy acid is a beta hydroxy acid, and the protects them against physical stress. Disruption of the beta hydroxy acid is salicylic acid or lipohydroxy acid. keratin scaffold leads to tissue and cell fragility in the skin 0009. In one aspect of the invention, the cannabinoid is and its appendages (hair, nail, glands), oral mucosa, and hemp oil or human breast milk. cornea, and exposes the skin to pathological conditions and 0010. In a different aspect of the invention, the cannabi diseases. noid is one or more of cannabigerolic acid (CBGA), can nabigerolic acid monomethylether (CBGAM), cannabigerol 0004 Dermatitis, also known as eczema, is an inflam (CBG), cannabigerol monomethylether (CBGM), cannab mation of the skin that is characterized by the presence of igerovarinic acid (CBGVA), cannabigerovarin (CBGV), itchy, erythematous, Vesicular, weeping, and crusting cannabichromenic acid (CBCA), cannabichromene (CBC), patches. Inflammatory agents include bacteria, fungi, cannabichromevarinic acid (CBCVA), cannabichromevarin viruses, and autoimmune, allergic, hormonal and malignant (CBCV), cannabidiolic acid (CBDA), cannabidiol (CBD), inflammatory agents. The most common skin diseases or cannabidiol monomethylether (CBDM), cannabidiol-C disorders include eczema, psoriasis, dermatitis, itching der (CBD-C), cannabidivarinic acid (CBDVA), cannabidivarin matosis, rosacea, perioral dermatitis, acne, non-melanoma (CBDV), cannabidiorcol (CBD-C), delta-9-tetrahydrocan skin cancer and melanoma. Although symptoms vary, recur nabinolic acid A (THCA-A), delta-9-tetrahydrocannabinolic rent dermatitis conditions include pruritus, dryness and skin acid B (THCA-B), delta-9-tetrahydrocannabinol (THC), rashes, which may be accompanied by redness, skin Swell delta-9-tetrahydrocannabinolic acid-C (THCA-C), delta ing, itching and dryness, crusting, flaking, blistering, crack 9-tetrahydrocannabinol-C (THC-C), delta-9-tetrahydro ing, oozing, or bleeding. Common forms of dermatitis cannabivarinic acid (THCVA), delta-9-tetrahydrocannabi include atopic dermatitis, an allergic disease characterized varin (THCV), delta-9-tetrahydrocannabiorcolic acid by the presence of itchy rashes, contact dermatitis, which (THCA-C), delta-9-tetrahydrocannabiorcol (THC-C), may be caused by an allergen or an irritant, Xerotic eczema, delta-7-cis-iso-tetrahydrocannabivarin, delta-8-tetrahydro which is caused by dry skin, and seborrheic dermatitis, cannabinolic acid (A-THCA), delta-8-tetrahydrocannabinol which is more common in infants. (A-THC), cannabicyclolic acid (CBLA), cannabicyclol 0005 Sunlight is a major cause of skin aging. Symptoms (CBL), cannabicyclovarin (CBLV), cannnabielsoic acid A of skin aging are wrinkles, age spots and dryness. While (CBEA-A), cannabielsoic acid B (CBEA-B), cannabielsoin treatment with moisturizers and steroid creams may tempo (CBE), cannabinolic acid (CBNA), cannabinol (CBN), can rarily control skin disorder and aging symptoms by reducing nabinol methylether (CBNM), cannabinol-C (CBN C), inflammation and Smoothing wrinkles, the relief is only cannabivarin (CBV), cannabinol-C (CBN C), cannabior temporary. There is no known cure for dermatitis, and col (CBN C), cannabinodiol (CBND), cannabinodivarin systemic side effects prevent long term treatment of chronic (CBVD), cannabitriol (CBT), 10-ethoxy-9-hydroxy-delta dermatological conditions with steroids. 6a-tetrahydrocannabinol, 8,9-dihydroxy-delta-6a-tetrahy US 2017/0042791 A1 Feb. 16, 2017 drocannabinol, cannabitriolvarin (CBTV), ethoxy-cannabit about 1 umol/cm. In one aspect of the invention, the subject riolvarin (CBTVE), dehydrocannabifuran (DCBF), is a mammal. In a preferred aspect of the invention, the cannabifuran (CBF), cannabichromanon (CBCN), can mammal is a human. nabicitran (CBT), 10-oxo-delta-6a-tetrahydrocannabinol 0017. In yet another embodiment, the invention provides (OTHC), delta-9-cis-tetrahydrocannabinol (cis-THC), 3,4,5, a method for treating or preventing pruritus, dryness of the 6-tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-pro skin, skin rash, redness, Swelling of the skin, itching, crust pyl-2,6-methano-2H-1-benzoxocin-5-methanol (OH-iso ing, flaking, blistering, cracking, oozing, bleeding or blis HHCV), cannabiripsol (CBR) and trihydroxy-delta-9- tering of the skin in a Subject in need thereof, that comprises